65,437 trials
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline — -0.48; -0.74 percentage point change
Alcohol Dependence
Primary: Percent of Patients Initiating Vivitrol Treatment Who Receive 3 Consecutive Monthly Vivitrol Injections — 40 Percent of participants
Weaning · Tracheostomy
Primary: Weaning Time — 4.95; 10.15; 4.95; 10.15 day
Constipation
Primary: Patient Preference in Terms of Overall Preference and Preference of Taste, Consistency, and Portability. — 7; 6; 12; 11 participants
Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26. — -0.19; -0.66; -0.80 percentage of Glycosylated Hemoglobin — p=<0.001
Type 2 Diabetes
Primary: Change in HbA1c Level From Baseline to Week 18 (LOCF) — 8.41; 8.28; 7.53; 7.93 Percent
Lung Cancer · Metastatic Cancer
Primary: Number of Patients With Intracranial Response — 3 participants
Metastatic Breast Cancer (MBC)
Primary: Time to Progressive Disease (TTPD) by Treatment Schedule — 8.33; 7.51 months — p=0.345
Chronic Kidney Disease
Primary: Fibroblast Growth Factor 23 (FGF-23) — 162.695; 297; 188.975; 143.7675 RU/ml
Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) — 125.5 days
Atherosclerosis
Primary: Omega-3 Index — 4.37; 4.71 % EPA+DHA in total red cell fatty acids
Varicella
Primary: Number of Participants With Any Serious Adverse Event — 0 participants
Hypogonadism
Primary: Percent Change From Baseline to Month 6 in Aging Male Symptoms (AMS) in Mean Total Score — -29.0 Percent Change
Type 2 Diabetes
Primary: Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c) — 8.33; 8.33; 7.82; 8.28 percent — p=0.0011
Jaw, Edentulous, Partially
Primary: Implant Survival Rate — 100 Percentage of implants